Comparative Study Between Alzheimer's and Multi-infarct Dementia
1 other identifier
observational
76
1 country
1
Brief Summary
Dementia is a neurological disease that causes cognitive and behavioral impairments that could ultimately interfere with the ability to function at work or to do the usual daily activities. It is recognized as a healthcare and social burden and remains challenging in terms of proper diagnosis and treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2023
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 20, 2023
CompletedStudy Start
First participant enrolled
March 10, 2023
CompletedFirst Posted
Study publicly available on registry
March 23, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 21, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 21, 2026
CompletedMarch 23, 2023
March 1, 2023
2.4 years
February 20, 2023
March 11, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
detect difference between multiple types of dementia (Alzheimer's disease with early onset, and late-onset as well as multi-infarct dementia )
detect difference between multiple types of dementia (Alzheimer's disease with early onset, and late-onset as well as multi-infarct dementia ) regarding clinical profile, biomarkers, and cortical excitability
2 years
Study Arms (4)
Early onset Alzhiemer
before age of 65 and above age of 50
Late onset Alzhiemer
Above the age of 65
Vascular dementia
Any patient diagnosed with vascular dementia
control group
persons who has no dementia
Interventions
the levels Neurofilaments (NfL) (Abcam, USA), C-X-C motif chemokine 13 (CXCL13) and Chitinase 3-like Protein 1 (Sigma-aldrich, Germany) will be determined in the serum and CSF (if available) in the different participant groups.
Eligibility Criteria
case control study, it will include 4 groups of dementia patients in early and late onset, and control healthy group matching with age, sex and educational state. The study will include 19 patient of each dementia type and 19 controls, each dementia patients were diagnosed according to the international classification of disease 10th revision ICD 10. Total score of Mini-mental state examination is \<24 or 22 in Mini-mental state examination will be used as a screening test for detection of cases.
You may qualify if:
- Men or women of at least 50-80 years of age.
- Are reliable in individual data and willing to make themselves available for the duration of the study
- Clear written informed consent obtained from 1st degree of relative from each patient participant and control himself in the trial.
You may not qualify if:
- age below 50 years and above 80 years.
- other neurological disorders or psychiatric disorders; previous history of stroke; metabolic disturbance; other major medical illnesses; epilepsy; inflammatory, autoimmune, or infectious disease; metallic objects in the body; craniotomy in the past.
- Presence of clinically significant medical or psychiatric condition that may increase the risk associated with the study
- Participation in any other type of medical research that may interfere with the interpretation of the study.
- Patients with severe motor disability (bed-ridden) that may interfere with the study procedure.
- Patients with history of seizures or epilepsy including history in a first degree relative
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Medicine
Asyut, Egypt
Related Publications (3)
Antczak J, Rusin G, Slowik A. Transcranial Magnetic Stimulation as a Diagnostic and Therapeutic Tool in Various Types of Dementia. J Clin Med. 2021 Jun 28;10(13):2875. doi: 10.3390/jcm10132875.
PMID: 34203558BACKGROUNDElshahidi MH, Elhadidi MA, Sharaqi AA, Mostafa A, Elzhery MA. Prevalence of dementia in Egypt: a systematic review. Neuropsychiatr Dis Treat. 2017 Mar 6;13:715-720. doi: 10.2147/NDT.S127605. eCollection 2017.
PMID: 28293113BACKGROUNDWeston PSJ, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K, Druyeh R, Malone IB, Ahsan RL, Pemberton H, Klimova J, Mead S, Blennow K, Rossor MN, Schott JM, Zetterberg H, Fox NC. Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology. 2017 Nov 21;89(21):2167-2175. doi: 10.1212/WNL.0000000000004667. Epub 2017 Oct 25.
PMID: 29070659BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Eman M Khedr, professor
Assiut University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Lecturer
Study Record Dates
First Submitted
February 20, 2023
First Posted
March 23, 2023
Study Start
March 10, 2023
Primary Completion
July 21, 2025
Study Completion
February 21, 2026
Last Updated
March 23, 2023
Record last verified: 2023-03
Data Sharing
- IPD Sharing
- Will not share